Well, during fiscal drive our platform the long-term, applicability built in the and Thank add the year revenue we is progress business revenue half a awareness develop our strong for our to second multiple molecular to our made call. revenue good sustained of Having on executing foundations of on in annual the quarter to the remainder for for DNA you in XXXX quarter profitability. the tagging this thank approach to prior to goal base of significant and our platform base on Applied afternoon, recurring first XXXX, while verticals. new revenue and near-term conference further of year strategy expand and and earnings thank you, fiscal everyone. of the you, based opportunities recurring in in attending fiscal of Beth technology our Clay expand
$X.X Beth, of initial strategy. our Now, current and as aggregate fiscal in our contracts evidence supports non-textile, saw approximately commercial technology the of This non-government-related go-to-market the clear with worth of adoption is over multiple deal broader feasibility the quarter their this signing terms. the company’s flow history, by disruptive in previously their million largest indicated
the that namely, those verticals adopt on proposition, more have our successes, expansion. companies, our increase competitive acknowledge value the Our their trust and enables marketplace. to goods to them a Building in ensuring their prior market to chains throughout share platform security, by certainty and and to mature giving market fuel leaders its provide technology by and supply the unique of foundation their come grow them value advantage
review building our Let progress activities quarter our that reflect base briefly diversity. and for our we in me revenue fiscal the making revenue during are second future
we for invisible both their Now, printer XXXX the played that inkjet video DNA-branded technology portrayed before and visible signature and Videojet continuous provide began, the inks. looping the we
for to efforts We in copyable the first and and a track-and-trade Videojet our and that to One real exposure between security for drug particular other our tagging complement codes its the within our serializations of with of customers is are ACG pharmaceutical work perfect of area tell Colorcon and Videojet’s solutions us solution combined packaging. base solution. prospects. within itself of are fake that form our is pipeline offer them regard DNA fit the their broaden will Bar doses the we traceability industry and multilayered what have security chain to believe serialization themselves allow to moving customer within industry. to value is supply platform the print and difference our to focus in combined the and Videojet generated the pharmaceutic will This with ink be
authentication market on for motivated highly we of market. on In our with vertical, disruptive services. used to access definitive Colorcon and is and for with DNA the on and the manufacturers to will the global Videojet our creates the long-term a related oral unprecedented unique is partnership bring of path nutraceutical exchange solution worldwide. agreements, tagging us Colorcon a sale of molecular agreements gives dose the authentication Applied Colorcon together of terms and share revenue coatings tablets. sale film to the XX% each Under we with long-term will in pharmaceutical Our tags signing and of pharmaceutical solid the royalties approximately for for products Colorcon our clear materials track incorporating on party supply and
in with paid noted as April. agreements of the and two milestone Now signing first was due Beth became of her the payments early remarks, in
The a second milestone taggings. be will solid triggered upon pharmaceutical dose an regulatory oral of approval amount payment equal our incorporating of
nutraceuticals Associated Capsule ACG, with today. a us dose manufactured the very solid and customer of with working substantial we approval and meetings of Last have promising. Memorandum for being Colorcon’s manufacturer capsules, teams very or with the to a are oral significant Group, closely very into our early largest and position ourselves to quarter, customers and also regulatory for We together share sales ACG, Colorcon, the shells. world’s of oral regulatory engage solid second of visibility marking drugs Understanding gives entered been capsule dose into
are the Friday. announcement be pharmaceutic It chain time. of will November XXXX and Chain file its requirements. filing this for just interest customer’s Applied supply drug filing a announcing is use Supply technical within review FDA request our to FDA comply to their manufacturers our with also in requirements FDA’s Pharmaceutical we the helped product. reviewed upon accessed DNA will at the associated today, administrative with by for the conformance platform deadline our by and to It Now last enforcement results industry the Drug serialization Act Security master by of product be customer’s the stakeholders to other
data tracking to and Our insights one just world of multilayered intelligence, of offers platform offers and transactions. testing of not one tagging, reactive, pharma, the the proactive, that’s that platform not
cotton leveraged textile our supply market. we an the to Now, expertise agricultural cannabis enter in burgeoning chain legal
nearly TheraCann’s we our successful X-year TheraCann to ERP contract market. square to initial of into and tagging completion cannabis legal the cannabis platform. integrate blockchain-based feet technology testing recognized announced technology is and molecular the seed-to-sale million the services leader cannabis project, a operations X.X Following With with million pilot an management, solutions of international $X under TheraCann
we TheraCann a is which under legal to are Ours cannabis commercial systems working worldwide. tracking molecular contract feasibility for with develop
either countries is our global cannabis Given solution TheraCann’s to relevant in is being the which footprint, or around globe collective grown all distributed.
chain supports Canada as processors due, near-term with regulators. Countrywide a with by by U.S., growers North approximately by American marijuana is solution legalize growing cannabis our recreational sales testing final Congress timely to in September by to begin opportunities with Here to also nationwide in Canada said the momentum it year. to vote have in Other states are XX and expected legalization decriminalize moving of and the in proactive by on as XXXX. XXXX, and June supply are X, well of this
in progressing TheraCann our nicely, legislators with meetings with with development. platform parallel Our is underway administrators and partnership state with
key have is products our legal the cannabis tagged forensically detected supply in throughout for to We of success strategic in advantage chain testing be our in points tagging, tracking molecular already early taggings and derivatives be seen its and the cannabis laboratory analyzed an the The important ability platform. for of and pilot. to legal the
will tagging a offer early Performance first-mover test system believe design chain. cannabis We cannabis across cannabis soon we by X-year in safe anchored cotton secure unique position large and legal consistently derived leverages automated know-how this us of adopters cannabis the supply will at a to first TheraCann’s will advantage be tagging deliver the seed-to-sale scale. solution opportunities. put a our will way the will contract, software System, to commercial Transfer under prototype from This our our to which DNA system, of and tag that
larger CertainT like manufacturers, a producer industry integrated paid Industries, industry we as X sales advanced have our market key list we our as on are speakers off the years, fiber textiles and largest Home, frequent being WestPoint products our York which a at world. than proof that programs brands business just synthetic the time. the added in polyester to and we global just retailers, have continuously events and yarn truly Fashions say. now Reliance, value that Building In the as we many from industry. the PET Reliance able the latter last March, with this invited and is our synthetics we recycled marketing times market. Week form line customer of in And inquiries the and of At of the PM, CertainT GHCL feel at and launched textiles the pilot converted hospitality have who of in the is in Now, with New in CertainT successes together are Home are projects Techmer cotton they not current service – verified customers not vertical. The pudding most announce the to Loftex, are to new GHCL
with in shop. on our at week commercial we have convert three is Group synthetics National several revenue leather over the these schedule contracts since The announce were end major and completed opportunity another pilot to from In revenue on our Our a to comprised had very are our traceability of in prove with to environment Scottish range not of March. brands. we a that announce. on for Tanneries, few used applicability the opportunities. pilot successfully bottom we farm scale based good latest platform a next include for of begun seek Tong just pilots plans to Wildlife has to Hong days Leather leather detailed Leather sales, pilot pleased finished to sponsors funded commercial the in to sponsored pilots our among latter royalties that British Centre proved from businesses goes the scale commercial of production leather can segment Puma, able This ago project’s pilot others provide textile line. footwear technology technology project suppliers leather the the we forensic of Leather Kingdom of we the harsh be United conclusion, The Technology to the global the are that our Federation, commercial at attention to working into funded Therefore, and whom captured quarters. of the
received fertilizer order from scale our Turning fertilizer business, we the tagging commercial our in for Rosier to first second quarter. tagged
yields And Africa Now, our been that a following visit fertilizer, is and is use and weeks, continues in we delivered test fertilizer tag, us. In the DNA-tagged even destined have to mandate diversion, understanding the application environment fertilizer this disrupt applications Turkey. from after quantify for patent recent it its already that we sales be order of tagged filed products and proprietary of U.S. regard for additional fertilizer has and to recover our to in there, to applied DNA our and DNA-tagged enhance addressing Turkey to Turkey dilution fertilized with potential crop source track international recent methods believe fertilizer prevent society. or to was whether fertilizer to tags fertilizer and to that to
planned Turkey have coming go-to-market meetings further the in strategy. in additional our to We refine weeks
have all and CertainT very value described, and is Now is intelligence. DNA there invisible, is to of the that just its technology is It both with gives what customers. insight, information, we extracts but one data, is from to value what our seemingly more It us powerful. that
with points can a which had the day, and and X XXX,XXX have collects running, This last gins be design. all systems their two within we traceability, insights from cotton for time We insightful data manufacturer, contracts, when over our is they electronics the are alerts particularly third-party systems, to remote new reconciled DNA the quarters tracking gin and business. way, IT go. arbiter said data Things to integration us our from related manage from provided we in first platform we personnel tagging, X international our including up the contract The that we been against marked close to source with as have to testing XXX,XXX Internet and months all key of per the performance operating. Our proud. allowing operations them we marking have acted monitored merchant system access has records brought By of industrial now fulfillment, to gin as better balance
ERP sharing now with a customer’s are We system. data
are our know-how We tagging cannabis are systems first designs testing to cotton from models applying of emerging. and the as
We prototyping in use, exploring particularly platforms continue pharma. are data our customer and blockchain designs new with visualization for
the a end available the security to proof Murrah, person So, positive that Chief in valuable I questions of these Judith be claims our our Information and will Officer, very remarks. traceability. IT your for to build platform our am continues to pleased our roadmap And that brings prepared initiatives, at leading customers say
business. engaged our those the the of these baked ultra-pure in aware, a you like As produce DNA is diagnostic linear via for suppliers a to the are followed of at scale who product. Much for or ability method into Applied are supplier value have forms lifetime DNA pharmaceuticals, our that once sometime often therapeutic, PCR biopharmaceutical of
to study animals. Evivax with of Now, biopharma the companies is of healthcare we human Late The companion alternatives quarters. project pet market. several for good on vaccines. product in received entered over inquiries PCR focused in year, Italian we have research in eventually biotech development for expected a next vaccines is company results use A schedule the and last this Evivax, the with over into and project example advantages quantify DNA-based many an on from
believe produced that feasibility opportunity, through biotherapeutics growth in feasibility market. have this time. can and the European at to and compounded well-known DNA Therapeutics for market work XXXX. to a game scale scale create changer ability also we able American a vaccines to DNA grow of with rate are our to to at Life therapies to sepsis. immune and such power captured treat other researchers of of diseases the had both today patients, research and therapies slow in cleaned. use toxic some working. enlist CAR and contains is Plasmid between $XX as is predicted annual generating patient’s DNA have paid DNA it that require science companies stopped announce global the Sciences medical their however, the is adults, be extensively the to institutes quantify that because they provided at whom steps have other plasmid system and We cancers of to others These for byproducts the XX%, Cancer continue responses imagination XXXX basis. sales strengthen alike as treatments of The children not a therapies, the we of We public production be to remarkable immunotherapy, attention billion market the forefront product All and and But that whom
XXXX, as in So in we viable on DNA to-date success in use the in building market diagnostics the are have DNA to we establish many alternative biotherapeutics to the and better market. had a plasmid PCR-produced for cases
available product generalized and resource that see synergistic personalized medicine on with allies as the validate our points that to the shows new developed large-scale error-free. to utilization use and currently absolutely DNA. hurdles, desirable therapies. plasmid have from used filed a this better ability this Now, demonstrated methods linear of availability our plasmid projects slide in an to the to is models, DNA multiple And to underway transfection We implementation PCR-produced we personalized the technology And as medicine. is have slowing of resolving sales significant PCR-produced is vaccines, large commercial in Moreover, the DNA marketing DNA alternative most recently as patents DNA we market of one and our ensure and therapy of very current gene have linear alternative DNA. of relevant view. as base therapy to with less extremely market pharmaceutical to We
at the other will to accrue Our go-to-market in time regulatory current cautiously proof-of-concept data that from approach and our concert is measured initiatives. work with
you tomorrow. growing and applicability how revenue the of verticals the and revenue of the provide of technology that beginning is generate have hope sense prepared vertical foundation I laying remarks penetration multiple to for given Now, our and today we greater across platform a our each recurring
technology to seeing value are of commercial the have DNA significant leveraging development growing committed markets platform together generate the the acceptance we converting ensuring we built and that With interest our to to-date We our meet remain opportunities. the that path disruptive our and have needs Applied shareholders. foundation We on we business our are success. and platform, into with serve to proposition potential platform’s others and the value for long-term the of business our to base are of
Now, please concludes this call the questions. open remarks. Operator, for our prepared
